AI주식인사이트AI Stock Insight
B

종근당

185750KOSPI

59.1 / 100

Reference Date: 2026-09-08

Financial Score24.5 / 40
News Sentiment18.6 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Slightly down 3.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Jonggun Pharm is a major South Korean pharmaceutical company established in 1941, specializing in both prescription and over-the-counter drugs. It invests 9-11% of its sales in R&D, focusing on new drug development and biosimilars, with key products including the anticancer drug 'Camtovel' and the diabetes treatment 'Duvie'. As of 2023, it holds approximately 5% of the domestic pharmaceutical market share.

Number of Employees

2,304people

Average Salary

79.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
11.63Industry Average 15.005.0Point

In line with industry avg

PBR
0.94Industry Average 1.204.0Point

In line with industry avg

ROE
8.18Industry Average 8.004.0Point

In line with industry avg

Debt Ratio
27.61Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲0.9% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼39.3% (2-year basis)

ROE Trend
2.5 / 4

Avg ROE 17.0% (declining, 3yr)

Detailed News Sentiment

29 totalPositive 21Neutral 5Negative 3Average Sentiment Score 74.5

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 68,400Won52-week high 97,70052-week low 64,100
1-month return2.0Point

1m -2.98% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-08-31
  • Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-08-28
  • Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-08-28
  • Neutral반기보고서 (2026.06)2026-08-14
  • Neutral주식등의대량보유상황보고서(약식)2026-08-13